{"id":"https://openalex.org/W45451995","doi":null,"title":"Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.","display_name":"Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.","alternate_titles":[],"publication_year":2009,"publication_date":"2009-07-01","ids":{"openalex":"https://openalex.org/W45451995","mag":"45451995","pmid":"https://pubmed.ncbi.nlm.nih.gov/19579178"},"language":"en","primary_location":{"id":"pmid:19579178","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19579178","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W45451995"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075804608","display_name":"Bruno Pietro Imbimbo","orcid":"https://orcid.org/0000-0002-0327-7262","observed_orcids":["https://orcid.org/0000-0002-0327-7262"]},"institutions":[{"id":"https://openalex.org/I4210162628","display_name":"Chiesi (Italy)","ror":"https://ror.org/0511bn634","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210162628"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Bruno P Imbimbo","raw_affiliation_strings":["Chiesi Farmaceutici SpA, Research & Development Department, Via Palermo 26/A, 43100 Parma, Italy. b.imbimbo@chiesigroup.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chiesi Farmaceutici SpA, Research & Development Department, Via Palermo 26/A, 43100 Parma, Italy. b.imbimbo@chiesigroup.com","institution_ids":["https://openalex.org/I4210162628"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019919419","display_name":"Ilaria Peretto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ilaria Peretto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.2746,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.7475406,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"10","issue":"7","first_page":"721","last_page":"730"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/semagacestat","display_name":"semagacestat","score":1.0},{"id":"https://openalex.org/keywords/gamma-secretase-inhibitors","display_name":"gamma-secretase inhibitors","score":0.9440000057220459},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.996999979019165},{"id":"https://openalex.org/keywords/amyloid-beta","display_name":"amyloid-beta","score":0.9570000171661377},{"id":"https://openalex.org/keywords/amyloid-plaques","display_name":"amyloid plaques","score":0.5329999923706055},{"id":"https://openalex.org/keywords/cognitive-decline","display_name":"cognitive decline","score":0.675000011920929},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.7350000143051147},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.7860000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7560692429542542},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6465922594070435},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5419231057167053},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5124202370643616},{"id":"https://openalex.org/C2776156579","wikidata":"https://www.wikidata.org/wiki/Q417667","display_name":"Amyloid beta","level":3,"score":0.46083906292915344},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.4534759819507599},{"id":"https://openalex.org/C2780942790","wikidata":"https://www.wikidata.org/wiki/Q372016","display_name":"Pathogenesis","level":2,"score":0.45324742794036865},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4501292407512665},{"id":"https://openalex.org/C2778171954","wikidata":"https://www.wikidata.org/wiki/Q15328541","display_name":"Gamma secretase","level":2,"score":0.44932255148887634},{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.43992146849632263},{"id":"https://openalex.org/C36103677","wikidata":"https://www.wikidata.org/wiki/Q4749551","display_name":"Amyloid precursor protein secretase","level":5,"score":0.43934163451194763},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40932270884513855},{"id":"https://openalex.org/C31705614","wikidata":"https://www.wikidata.org/wiki/Q423510","display_name":"Amyloid precursor protein","level":4,"score":0.28187623620033264},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0747937560081482},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.04905891418457031},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000409","descriptor_name":"Alanine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000409","descriptor_name":"Alanine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000409","descriptor_name":"Alanine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000409","descriptor_name":"Alanine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010330","descriptor_name":"Patents as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053829","descriptor_name":"Amyloid Precursor Protein Secretases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:19579178","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19579178","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:45451995","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19579178","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W2075481535","https://openalex.org/W2109727228","https://openalex.org/W2114655589","https://openalex.org/W2117618489","https://openalex.org/W2154144191","https://openalex.org/W2164975702","https://openalex.org/W2172066391"],"related_works":["https://openalex.org/W2061286463","https://openalex.org/W1507912961","https://openalex.org/W2065706231","https://openalex.org/W2147937910","https://openalex.org/W2118935254","https://openalex.org/W1986623185","https://openalex.org/W2116961882","https://openalex.org/W13161764","https://openalex.org/W2762387701","https://openalex.org/W2035000249"],"abstract_inverted_index":{"Eli":[0,168],"Lilly":[1],"&":[2],"Co":[3],"is":[4,15,171],"developing":[5],"semagacestat,":[6],"an":[7],"inhibitor":[8,176],"of":[9,20,35,60,115,132,189,192],"the":[10,18,33,47,138,149,172,187],"gamma-secretase":[11,175],"enzyme.":[12],"This":[13],"enzyme":[14],"pivotal":[16],"in":[17,32,46,67,83,102,124,137,160],"generation":[19],"beta-amyloid":[21],"(A":[22],"beta),":[23],"a":[24,112,121,128,179],"neurotoxic":[25],"endogenous":[26],"peptide":[27],"believed":[28],"to":[29,76,93,98,185],"be":[30],"involved":[31,148],"pathogenesis":[34],"Alzheimer's":[36],"disease":[37],"(AD).":[38],"In":[39,152],"animals,":[40],"semagacestat":[41],"reduced":[42],"A":[43,117,135],"beta":[44,118,136],"levels":[45],"plasma,":[48],"CSF":[49,139],"and":[50,79,106,120,177],"brain;":[51],"however,":[52],"studies":[53],"have":[54,70,87,110],"not":[55],"reported":[56],"on":[57],"cognitive":[58,190],"effect":[59],"this":[61],"compound.":[62],"Phase":[63],"I":[64],"clinical":[65,158],"trials":[66,82,159],"healthy":[68,104,125],"volunteers":[69,105,126],"evaluated":[71,88],"doses":[72,89],"ranging":[73,90],"from":[74,91],"5":[75],"140":[77,94],"mg/day":[78,95],"phase":[80,156],"II":[81],"patients":[84,107,161,193],"with":[85,108,162,194],"AD":[86,109,164],"30":[92],"for":[96],"up":[97],"14":[99],"weeks.":[100],"Trials":[101],"both":[103],"demonstrated":[111,127],"dose-dependent":[113,130],"inhibition":[114,131],"plasma":[116],"levels,":[119],"recent":[122],"trial":[123],"robust,":[129],"newly":[133],"generated":[134],"after":[140],"single":[141],"oral":[142],"doses.":[143],"The":[144],"main":[145],"adverse":[146],"events":[147],"gastrointestinal":[150],"tract.":[151],"2008,":[153],"two":[154],"large":[155],"III":[157],"mild-to-moderate":[163],"were":[165],"initiated":[166],"by":[167],"Lilly.":[169],"Semagacestat":[170],"most":[173],"advanced":[174],"represents":[178],"major":[180],"hope":[181],"among":[182],"therapies":[183],"designed":[184],"slow":[186],"rate":[188],"decline":[191],"AD.":[195]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W45451995","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
